Incyte (INCY) Total Debt (QoQ) (2012 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.28% |
| Dec 31, 2025 | -9.82% |
| Sep 30, 2025 | -2.60% |
| Jun 30, 2025 | 12.29% |
| Mar 31, 2025 | 6.32% |
| Dec 31, 2024 | -2.72% |
| Sep 30, 2024 | 8.56% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -3.28% |
| Dec 31, 2023 | 4.37% |
| Sep 30, 2023 | -1.85% |
| Jun 30, 2023 | 0.91% |
| Mar 31, 2023 | 1.73% |
| Dec 31, 2022 | 6.88% |
| Sep 30, 2022 | -7.39% |
| Jun 30, 2022 | -2.53% |
| Mar 31, 2022 | 2.34% |
| Dec 31, 2021 | -3.17% |
| Sep 30, 2021 | -4.42% |
| Jun 30, 2021 | 0.20% |
| Mar 31, 2021 | 3.92% |
| Dec 31, 2020 | -1.66% |
| Sep 30, 2020 | 110.08% |
| Jun 30, 2020 | 0.35% |
| Mar 31, 2020 | -45.59% |
| Jun 30, 2019 | 4.94% |
| Mar 31, 2019 | 7.52% |
| Dec 31, 2018 | 316.37% |
| Sep 30, 2018 | 1.24% |
| Jun 30, 2018 | -73.19% |
| Mar 31, 2018 | 281.10% |
| Dec 31, 2017 | -69.61% |
| Sep 30, 2017 | 6.81% |
| Jun 30, 2017 | 5.81% |
| Mar 31, 2017 | 10.18% |
| Dec 31, 2016 | 9.44% |
| Sep 30, 2016 | 0.94% |
| Sep 30, 2015 | -99.99% |
| Jun 30, 2015 | -50.83% |
| Mar 31, 2015 | 2.53% |
| Sep 30, 2012 | 1.40% |
| Jun 30, 2012 | 1.40% |